Medical and economic significance and calculation of economic treatment costs of a patient with hidradenitis suppurativa in the Russian Federation

Close metadata

BACKGROUND

Hidradenitis suppurativa (HS) is a chronic recurrent disease. The high cost of HS and its complications treatment, long periods of temporary disability and the development of incapacity force to find ways of the quality of patients’ life improvement and the socio-economic burden reduction.

OBJECTIVE

Assessment of the economic burden and economic prospects of genetically engineered biological drugs (GEBD) provision to HS patients in the Russian Federation.

MATERIAL AND METHODS

An analysis of the HS prevalence on the basis of data from epidemiological studies, statistical indicators of the Ministry of Health of the Russian Federation and assessments of specialized professionals was carried out. A mathematical variable-based model for the calculation of HS economic burden in the Russian Federation has been developed. It allows to determine direct and indirect financial costs associated with the treatment of the main disease and its complications, loss from temporary and persistent disability, development of incapacity.

RESULTS

The economic burden without the use of GEBD on one HS patient was almost 300 thousand. rub., on the population of HS patients — 43.9 billion rub. Provision of GEBD to only 5% of the most severely ill HS patients will reduce the duration of temporary disability by 65%, the level of incapacity by 90%, and reduce the annual economic burden from 43.9 billion to 29.0 billion rub. Substantial saving of budget funds is expected from the third year of GEBD implementation, thus the quality of patients’ life is improved after the first 12 weeks of therapy and significantly higher during the first year.

CONCLUSION

The provision of HS patients with GEBD is a promising direction for improving the health care delivery and is economically feasible. Adjustments in a number of laws and regulations are necessary in order to provide GEBD accessibility.

Keywords:

hidradenitis suppurativa

epidemiology

genetically engineered biological drugs

economic and social burden

drug provision

laws and regulations

Authors:

Raznatovsky K.I.

North-Western State Medical University named after I.I. Mechnikov

ORCID: 0000-0003-1022-7463

Khairutdinov V.R.

Kirov Military medical academy

ORCID: 0000-0002-0387-5481

Dreval R.O.

Center of Social Economy

SPIN RSCI: 5531-3443
Scopus AuthorID: 57219921997
ORCID: 0000-0002-5109-7725

Zabotina A.N.

Center of Social Economy

ORCID: 0000-0003-0378-9740

Received:

12.03.2024

Accepted:

02.04.2024

List of references:

Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020; 82(5):1045-1058. https://doi.org/10.1016/j.jaad.2019.08.090
Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50-61. https://doi.org/10.1111/jdv.16677
Vinding GR, Miller IM, Zarchi K, Ibler KS, Ellervik C, Jemec GB. The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa. Br J Dermatol. 2014;170(4):884-889. https://doi.org/10.1111/bjd.12787
Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Bastuji-Garin S. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009;61:51-57. https://doi.org/10.1016/j.jaad.2009.02.013
Tiri H, Huilaja L, Jokelainen J, Timonen M, Tasanen K. Women with hidradenitis suppurativa have an elevated risk of suicide. J Invest Dermatol. 2018;138:2672-2674. https://doi.org/10.1016/j.jid.2018.06.171
Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. 2018;138:52-57. https://doi.org/10.1016/j.jid.2017.09.008
Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, Esmann S, Thorlacius L, Villumsen B, Marmol VD, Nassif A, Delage M, Tzellos T, Moseng D, Grimstad Ø, Naik H, Micheletti R, Guilbault S, Miller AP, Hamzavi I, van der Zee H, Prens E, Kappe N, Ardon C, Kirby B, Hughes R, Zouboulis CC, Nikolakis G, Bechara FG, Matusiak L, Szepietowski J, Glowaczewska A, Smith SD, Goldfarb N, Daveluy S, Avgoustou C, Giamarellos-Bourboulis E, Cohen S, Soliman Y, Brant EG, Akilov O, Sayed C, Tan J, Alavi A, Lowes MA, Pascual JC, Riad H, Fisher S, Cohen A, Paek SY, Resnik B, Ju Q, Wang L, Strunk A. Evaluating patients’ unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2): 366-376. https://doi.org/10.1016/j.jaad.2019.06.1301
Sayed CJ, Hsiao JL, Okun MM; Clinical Epidemiology and Management of Hidradenitis Suppurativa. Hidradenitis Suppurativa Foundation Women’s Health Subcommittee. Obstet Gynecol. 2021;137(4):731-746. https://doi.org/10.1097/AOG.0000000000004321
Frew JW, Hawkes JE, Krueger JG. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. F1000Research. 2018;7:1930. https://doi.org/10.12688/f1000research.17267.1
Vossen ARJ V, van der Zee HH, Prens EP. Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. Front Immunol. 2018;9:2965. https://doi.org/10.3389/fimmu.2018.02965
Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk, R RH, eds. Dermatologic Surgery, Principles and Practice. second Edi. New York: Marcel Dekker; 1989;623-646.
van der Zee HH, Jemec GBE. New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes. J Am Acad Dermatol. 2015;73(5 suppl 1):S23-26. https://doi.org/10.1016/j.jaad.2015.07.047
Thorlacius L, Garg A, Riis PT, Nielsen SM, Bettoli V, Ingram JR, Del Marmol V, Matusiak L, Pascual JC, Revuz J, Sartorius K, Tzellos T, van der Zee HH, Zouboulis CC, Saunte DM, Gottlieb AB, Christensen R, Jemec GBE. Interrater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. Br J Dermatol. 2019;463. https://doi.org/10.1111/bjd.17716
Scuderi N, Monfrecola A, Dessy LA, Fabbrocini G, Megna M, Monfrecola G. Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review. Skin Appendage Disord. 2017;3(2):95-110. https://doi.org/10.1159/000462979
Ocker L, Abu Rached N, Seifert C, Scheel C, Bechara FG. Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review. J Clin Med. 2022;11(23):7240. https://doi.org/10.3390/jcm11237240
Thorlacius L, Ingram JR, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle R, Nielsen SM, Christensen R, Garg A, Jemec GBE; HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). British Journal of Dermatology. 2018;179(3):42-650. https://doi.org/10.1111/bjd.16672
Matusiak L, Szczech J, Kaaz K, Lelonek E, Szepietowski JC. Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa. Acta Derm Venereol. 2018;98(2):191-194. https://doi.org/10.2340/00015555-2815
Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peris K. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study. Br J Dermatol. 2021;184(1): 133-140. https://doi.org/10.1111/bjd.18983
Matusiak Ł, Szczęch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670-675. https://doi.org/10.1016/j.jaad.2016.10.042

Close metadata